Claims for Patent: 11,904,046

Summary for Patent: 11,904,046

Title:	Hydrocortisone oral liquid formulations
Abstract:	Provided herein are oral liquid formulations of hydrocortisone. Also provided herein are methods of making and using hydrocortisone oral liquid compositions for the treatment of certain diseases including endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases, and others.
Inventor(s):	Danka Radosavljevic, Sean Brynjelsen, Romona BHATTACHARYA, Kalyan Kathala
Assignee:	Eton Pharmaceuticals Inc
Application Number:	US18/113,458
Patent Claims:	1. A liquid pharmaceutical composition comprising: hydrocortisone or a pharmaceutically acceptable salt thereof, and a nonaqueous liquid carrier, wherein the nonaqueous liquid carrier comprises glycerin, wherein the nonaqueous liquid carrier optionally further comprises propylene glycol, polyethylene glycol (PEG), alcohol, or a combination thereof, and wherein the glycerin is present in the liquid pharmaceutical composition in an amount of about 40% to about 80% w/v; wherein the liquid pharmaceutical composition is an oral solution, and wherein the liquid pharmaceutical composition contains less than 5% weight by weight (% wt) of water. 2. The liquid pharmaceutical composition of claim 1, wherein the hydrocortisone or a pharmaceutically acceptable salt thereof is present in the liquid pharmaceutical composition in an amount of about 1 mg/mL. 3. The liquid pharmaceutical composition of claim 1, wherein the liquid pharmaceutical composition contains less than 3% wt of water. 4. The liquid pharmaceutical composition of claim 1, wherein the liquid pharmaceutical composition is nonaqueous. 5. The liquid pharmaceutical composition of claim 1, wherein the liquid pharmaceutical composition contains no more than 2% wt of total impurity after stored at room temperature for 3 months, and wherein the total impurity is determined according to high-performance liquid chromatography (HPLC). 6. The liquid pharmaceutical composition of claim 1, wherein the liquid pharmaceutical composition retains at least 95% wt of the initial hydrocortisone amount after stored at room temperature for 3 months, and wherein the hydrocortisone amount is determined according to HPLC. 7. The liquid pharmaceutical composition of claim 1, wherein the liquid pharmaceutical composition remains stable after stored at ambient conditions for at least 3 months. 8. The liquid pharmaceutical composition of claim 1, wherein PEG has a number average molecular weight of about 350 to about 450 g/mol, and wherein PEG is present in the liquid pharmaceutical composition in an amount of about 30% to about 70% w/v. 9. The liquid pharmaceutical composition of claim 1, wherein propylene glycol is present in the liquid pharmaceutical composition in an amount of about 0.5% to about 10% w/v. 10. The liquid pharmaceutical composition of claim 1, wherein the liquid pharmaceutical composition comprises a preservative, and wherein the preservative comprises an antimicrobial agent, a chelating agent, or an antioxidant, or any combinations thereof. 11. The liquid pharmaceutical composition of claim 10, wherein the antimicrobial agent comprises methyl paraben, ethyl paraben, propyl paraben, benzoic acid or a pharmaceutically acceptable salt thereof, sorbic acid or a pharmaceutically acceptable salt thereof, phenoxyethanol, benzyl alcohol, propionic acid, or a combination thereof, wherein the chelating agent comprises disodium ethylenediaminetetraacetic acid, polyphosphates, citric acid, calcium disodium edetate, ethylenediaminetetraacetic acid (EDTA), or a combination thereof, and wherein the antioxidant comprises vitamin A, monothioglycerol, ascorbic acid, sodium bisulfite, sodium sulfite, a-Tocopherol acetate (vitamin E), butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), or a combination thereof. 12. The liquid pharmaceutical composition of claim 1, wherein the liquid pharmaceutical composition comprises a flavoring agent, and wherein the flavoring agent comprises vanillin, grape flavor, caramel flavor, maltol, raspberry flavor, fruity flavor, berry flavor, 4-hydroxy-3-methoxybenzaldehyde, methyl anthranilate, 3,5-dimethyl-1,2-cyclopentadione, 4-(4-hydroxyphenyl)butan-2-one, ethyl maltol, ethyl propionate, or a combination thereof. 13. The liquid pharmaceutical composition of claim 1, wherein the liquid pharmaceutical composition comprises a sweetener, wherein the sweetener is glucose, fructose, sucrose, xylitol, tagatose, sucralose, maltitol, isomaltulose, hydrogenated isomaltulose, lactitol, sorbitol, erythritol, trehalose, maltodextrin, polydextrose, or a combination thereof. 14. The liquid pharmaceutical composition of claim 1, wherein hydrocortisone or a pharmaceutically acceptable salt thereof is present in the liquid pharmaceutical composition in an amount of about 0.05% to about 0.5% w/v; wherein the nonaqueous liquid carrier comprises propylene glycol, glycerin, and polyethylene glycol 400 (PEG 400), wherein propylene glycol is present in the liquid pharmaceutical composition in an amount of about 2% to about 10% w/v, wherein PEG 400 is present in the liquid pharmaceutical composition an amount of about 20% to about 70% w/v, and wherein glycerin is present in the liquid pharmaceutical composition in an amount of about 40% to about 80% w/v; wherein the liquid pharmaceutical composition further comprises: a preservative comprising an antioxidant and an antimicrobial agent, wherein the antioxidant comprises BHA, BHT, or a combination thereof, and wherein the antimicrobial agent comprises methyl paraben, ethyl paraben, propyl paraben or a combination thereof, a sweetener, and wherein the sweetener comprises glucose, fructose, sucrose, xylitol, tagatose, sucralose, maltitol, or a combination thereof, and a flavoring agent, and wherein the flavoring agent comprises berry flavor, maltol, ethyl maltol, or a combination thereof. 15. The liquid pharmaceutical composition of claim 1, comprising hydrocortisone or a pharmaceutically acceptable salt thereof in the liquid pharmaceutical composition in an amount of about 0.1% w/v; PEG 400 in the liquid pharmaceutical composition in an amount of about 50% w/v; BHA in the liquid pharmaceutical composition in an amount of about 0.01% w/v; a mixture of parabens in the liquid pharmaceutical composition in an amount of about 0.2% w/v; sucralose in the liquid pharmaceutical composition in an amount of about 1% w/v; berry flavor in the liquid pharmaceutical composition in an amount of about 0.2% w/v; propylene glycol in the liquid pharmaceutical composition in an amount of about 5% w/v; ethyl maltol in the liquid pharmaceutical composition in an amount of about 0.2% w/v; and glycerin in the liquid pharmaceutical composition in an amount of about 62.2% w/v. 16. A method of treating a disease or condition, comprising administering the liquid pharmaceutical composition of claim 1, to a subject in need thereof. 17. The method of claim 16, wherein the disease or condition comprises inflammation. 18. The method of claim 16, wherein the disease or condition is selected from endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, gastrointestinal diseases, acute exacerbation in multiple sclerosis, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculous chemotherapy, trichinosis with neurologic or myocardial involvement, and hypercalcemia. 19. A kit comprising a package enclosing the liquid pharmaceutical composition of claim 1. 20. The method of claim 16, wherein the disease or condition is adrenal insufficiency. 21. A liquid pharmaceutical composition comprising: hydrocortisone or a pharmaceutically acceptable salt thereof, and a nonaqueous liquid carrier, wherein the nonaqueous liquid carrier comprises polyethylene glycol (PEG), wherein the nonaqueous liquid carrier optionally further comprises propylene glycol, glycerin, alcohol, or a combination thereof, wherein the PEG has a number average molecular weight of about 350 to about 450 g/mol, and wherein the PEG is present in the liquid pharmaceutical composition in an amount of about 30% to about 70% w/v; wherein the liquid pharmaceutical composition is an oral solution, and wherein the liquid pharmaceutical composition contains less than 5% weight by weight (% wt) of water. 22. The liquid pharmaceutical composition of claim 21, wherein the hydrocortisone or a pharmaceutically acceptable salt thereof is present in the liquid pharmaceutical composition in an amount of about 1 mg/mL. 23. The liquid pharmaceutical composition of claim 21, wherein the liquid pharmaceutical composition remains stable after stored at ambient conditions for at least 3 months. 24. The liquid pharmaceutical composition of claim 21, wherein propylene glycol is present in the liquid pharmaceutical composition in an amount of about 0.5% to about 10% w/v. 25. The liquid pharmaceutical composition of claim 21, wherein glycerin is present in the liquid pharmaceutical composition in an amount of about 40% to about 80% w/v. 26. The liquid pharmaceutical composition of claim 21, wherein the liquid pharmaceutical composition comprises a preservative, and wherein the preservative comprises an antimicrobial agent, a chelating agent, or an antioxidant, or any combinations thereof. 27. The liquid pharmaceutical composition of claim 21, wherein the liquid pharmaceutical composition comprises a flavoring agent, a sweetener, or any combinations thereof. 28. A method of treating a disease or condition, comprising administering the liquid pharmaceutical composition of claim 21, to a subject in need thereof. 29. The method of claim 28, wherein the disease or condition is selected from the group consisting of adrenal insufficiency, inflammation, endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, gastrointestinal diseases, acute exacerbation in multiple sclerosis, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculous chemotherapy, trichinosis with neurologic or myocardial involvement, and hypercalcemia. 30. A kit comprising a package enclosing the liquid pharmaceutical composition of claim 21.